Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple Myeloma

NCT00523848 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

46

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma and Plasma Cell Neoplasm

Interventions

DRUG: bortezomib
DRUG: pegylated liposomal doxorubicin hydrochloride
DRUG: thalidomide

Sponsor

Roswell Park Cancer Institute